Navigation Links
PharmAthene Reports First Quarter 2011 Financial and Operating Results
Date:5/11/2011

er the Company's SparVax™ program and the completion of patient dosing in the Phase I Valortim® dose escalation clinical trial, partially offset by the decrease in development expenses related to the Protexia® bioscavenger program, which was completed in 2010.

General and administrative expenses for the Company were $4.9 million and $5.3 million for the quarters ended March 31, 2011 and 2010, respectively.  The decrease in general and administrative expense during the most recent period resulted from cost reductions implemented during 2010 and a reduction in bad debt expense, partially offset by an increase in legal costs associated with the trial in the case against SIGA.

For the first quarter of 2011 PharmAthene's net loss attributable to common shareholders was $2.1 million, or $0.04 per share, compared to $7.9 million, or $0.28 per share, in the same period of 2010.  The year-over-year decrease in net loss includes the impact of the change in fair value of the Company's derivative instruments, which was $2.5 million for the three months ended March 31, 2011 compared to $0.3 million for the three months ended March 31, 2010. The decrease in fair value, which became a source of other income, was primarily associated with a decrease in PharmAthene's stock price from December 31, 2010 to March 31, 2011.

As of March 31, 2011, the Company had cash and cash equivalents, short-term investments, and net U.S. government accounts receivables and other receivables, including unbilled receivables, totaling approximately $18.7 million compared to $21.6 million at December 31, 2010.  The decrease at March 31, 2011 was primarily attributable to the net impact of cash used to fund operations.

"We continued to make steady progress in the first quarter of 2011 and achieved important program milestones," remarked Eric I. Richman, President and Chief Executive Officer. "We achieved several technical milestones with respect
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
2. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
3. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
4. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
5. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
6. PharmAthene Announces Pricing of $15 Million Public Offering
7. PharmAthene Announces Proposed Common Stock Offering
8. PharmAthene Announces $3.9 Million Registered Direct Offering
9. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
10. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
11. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...  Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... a privately held company based in ... a big data platform for centralized management and ... proprietary on-market Genomic Management Solution, Bina-GMS 1 , ... fast and scalable analyses to maximize the value ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... pharmacies, has an expanded team of Regional Pharmaceutical ... for prescriber offices in their regions, with specific ... have a variety of Regional Pharmaceutical Care Liaisons ... in hepatitis C help prescribers understand all the ...
(Date:12/19/2014)... Reports from CDC show approximately 117 ... or more chronic health conditions - including cardiovascular disease, ... of these diseases, but may not eliminate the severe ... implanted nerve stimulation devices today offer relief, they require ... induce side effects. , To eliminate the need ...
(Date:12/19/2014)... 18, 2014 With only 2 weeks ... special on Sartorius Biohit products . The product specials ... Picus Electronic Pipette Trade-in Program, and free pipette tips. ... officers around the world. They are ideal for lab ... include:, ,     Full volume range of 0.1 ...
Breaking Biology Technology:Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
... Germany and OXFORD, England, November 28, Evotec AG ... Polywka and Dr Klaus Maleck have been appointed ... Officer and,Chief Financial Officer., Jorn Aldag, President ... extremely pleased to announce the addition of Dr ...
... Nov. 27 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... and,medical device company, is scheduled to participate in ... being held December 2 - 4 in Orlando, ... will give a 15-minute,formal presentation followed by a ...
... listing includes over 4,000 antibody products with documented ... ... Sigma-Aldrich(TM) (Nasdaq:,SIAL) is pleased to announce the new 2007-2008 ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071127/AQTU011 ), The 320-page Sigma Antibodies ...
Cached Biology Technology:Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 2Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 3Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 4Sigma-Aldrich Announces Launch of a New Antibodies Catalog 2Sigma-Aldrich Announces Launch of a New Antibodies Catalog 3
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... -- That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ... best ways to treat it. For example, a ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... in the two chromosomes has given scientists a break ... College of Georgia researchers report. It,s also helped ... no sense of smell, said Dr. Lawrence C. Layman, ... and Genetics. The WRD11 gene interacts with a ...
... The National Institute of General Medical Sciences (NIGMS) ... of Yeshiva University a five-year, $30 million grant to ... important proteins. "Determining the structures of proteins is ... biological processes as well as in disease pathways," says ...
... An Australian study of identical twins shows that a rare ... mutation that occurs in the embryo, and not necessarily passed ... University of Melbourne and Austin Health and published in the ... Director of the Comprehensive Epilepsy Program at Austin Health and ...
Cached Biology News:Chromosomal break gives scientists a break in finding new puberty gene 2Chromosomal break gives scientists a break in finding new puberty gene 3Einstein receives $30 million to study protein form and function 2Einstein receives $30 million to study protein form and function 3Einstein receives $30 million to study protein form and function 4
... salt solution. It is routinely used as an ... blood at refrigerator temperatures for approximately 10 weeks.1 ... collected into a container of this product and ... in a refrigerator at 2-8 C for 2 ...
... OligoMix or individual RNA sequences from high throughput ... small RNAs from LC Sciences. These products provide ... millions) of DESIGNED sequences delivered in a microtube ... containing a single verified RNA sequence. This is ...
... Chromatograph/Mass Spectrometer, utilizing many of the ... offers high throughput and excellent productivity, ... ratio. Like the GCMS-QP2010 Plus, the ... for optimum separation, 20 temperature ramps, ...
... Assay Kit contains all reagents necessary to ... lineage, as determined by staining for mineralization. ... necessary reagents and a protocol for quantifying ... product is useful for studying the effects ...
Biology Products: